Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
OSI Pharmaceuticals, Inc. Patents
Assignee:
OSI Pharmaceuticals, Inc.
Address:
Melville, NY
No. of patents:
81
Patents:


1 2










Patent Number Title Of Patent Date Issued
RE41065 Alkynl and azido-substituted 4-anilinoquinazolines December 29, 2009
The invention relates to compounds of the formula ##STR00001## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as
7951549 Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their form May 31, 2011
The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line H358, which are stimulated by receptor ligands to induce
7943767 Fused bicyclic mTOR inhibitors May 17, 2011
Compounds represented by Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
7939272 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor k May 10, 2011
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, co
7923555 Fused bicyclic mTor inhibitors April 12, 2011
Compounds represented by Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
7879566 Methods for the identification of modulators of OSGPR114 or OSGPR78 activity, and their use in t February 1, 2011
This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical a
7829717 (Arylamidoaryl)squaramide compounds November 9, 2010
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R.sup.5, m and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (
7820662 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors October 26, 2010
Compounds of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, R.sup.1, and Q.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperpr
7816325 Secondary binding site of dipeptidyl peptidase IV (DP IV) October 19, 2010
The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to comp
7790902 Isothiazole derivatives useful as anticancer agents September 7, 2010
The present invention relates to compounds of the formula 1 ##STR00001## and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X.sup.1, R.sup.1, R.sup.2 and R.sup.3 are as defined herein. The invention also relates to pharmaceutical compositions containing the
7767673 N-substituted imidazopyridine c-Kit inhibitors August 3, 2010
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-Oxide thereof, are useful in the treatment of cancer.
7741324 Imidazotriazines as protein kinase inhibitors June 22, 2010
Compounds of the formula ##STR00001## and pharmaceuticaly acceptable salts thereof, wherein Q.sup.1 and R.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition
7700594 Fused bicyclic mTOR inhibitors April 20, 2010
Compounds represented by Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
7696225 (2-carboxamido)(3-Amino) thiophene compounds April 13, 2010
Amidoaryl/amidoheteroaryl substituted thiophenes, further substituted with a heteroarylmethylamino group, are useful in the treatment of cancer.
7662844 Naphthylene derivatives as cytochrome P450 inhibitors February 16, 2010
Compounds of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G.sup.1, Q.sup.1, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5a, and R.sup.5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the tr
7659274 Unsaturated mTOR inhibitors February 9, 2010
Compounds represented by Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
7651687 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the January 26, 2010
The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibito
7648987 Bicyclic protein kinase inhibitors January 19, 2010
Compounds of the Formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, R.sup.1, and Q.sup.1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and/or prevention of h
7645754 Pyrrolopyrimidine A.sub.2B selective antagonist compounds, their synthesis and use January 12, 2010
The subject invention provides compounds having the structure: ##STR00001## wherein, R.sub.1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, --C(.dbd.O)NR.sub.aR.sub.b, --NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.b, --NR.
7618965 (Arylamidoanilino)nitroethylene compounds November 17, 2009
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R.sup.1, R.sup.2, and R.sup.5 are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal str
7608577 Peptidyl ketones as inhibitors of DPIV October 27, 2009
The present invention relates to compounds of the general formula 1 ##STR00001## and pharmaceutically acceptable salts thereof, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic n
7598252 Compounds specific to adenosine A, receptors and uses thereof October 6, 2009
This invention pertains to compounds which specifically inhibit the adenosine A.sub.1 receptor and the use of these compounds to treat a disease associated with A.sub.1 adenosine receptors in a subject.
7566721 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors July 28, 2009
Compounds of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein X.sub.1, X.sub.2, X.sub.3, and Q.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammatio
7534797 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors May 19, 2009
Compounds of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, R.sup.1, and Q.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hype
7524859 (2-carboxamido)(3-amino)thiophene compounds April 28, 2009
A method of treatment of hyperproliferative disorders comprises a step of administering an effective amount of a compound represented by ##STR00001##
7524638 Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the t April 28, 2009
This invention relates to the identification of LPA as a ligand for the G-protein coupled receptors OSGPR114 and OSGPR78. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR114 or OSGPR78, and new pharmaceutical a
7521456 N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrat April 21, 2009
The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate an
7521448 N-substituted benzimidazolyl c-Kit inhibitors April 21, 2009
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
7504407 Compounds specific to adenosine A.sub.1 and A.sub.3 receptors and uses thereof March 17, 2009
This invention pertains to compounds having the structure: ##STR00001## wherein m is 0, 1, 2, or 3; R.sub.2 is a substituted or unsubstituted imidazole or pyrazole wherein the point of attachment of R.sub.2 to the alkyl chain is not N; R.sub.5 is a hydrogen atom or a substituted or
7501407 Pyrimidine A.sub.2B selective antagonist compounds, their synthesis and use March 10, 2009
The subject invention provides compounds having the structure: ##STR00001## wherein R.sub.1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R.sub.2 is hydrogen, or a substituted or unsubstituted alkyl,
7498354 Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders March 3, 2009
or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors and cancers. ##STR00001##
7485658 N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors February 3, 2009
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
7465726 Substituted pyrrolo[2.3-B]pyridines December 16, 2008
Compounds represented by Formula (I): ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3.beta., EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ro
7459554 Imidazopyrazine tyrosine kinase inhibitors December 2, 2008
Compounds of the formula ##STR00001## and pharmaceutically acceptable salts thereof, wherein Q.sup.1 and R.sup.1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition
7442709 N3-substituted imidazopyridine c-Kit inhibitors October 28, 2008
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
7429574 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use September 30, 2008
Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.
7419995 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library September 2, 2008
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazole compounds represented by Formula (II): ##STR0
7405218 Isothiazole derivatives useful as anticancer agents July 29, 2008
The present invention relates to compounds of the formula 1 ##STR00001## and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X.sup.1, R.sup.1, R.sup.2 and R.sup.3 are as defined herein. The invention also relates to pharmaceutical compositions containing the
7405210 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase July 29, 2008
Compounds represented by Formula (I): ##STR00001## or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia,
7388012 (Hydrazido)(amino)thiophene compounds June 17, 2008
Compounds represented by Formula (I): ##STR00001## or a pharmaceutically acceptable salt or N-oxide thereof, wherein A and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ ce
7160890 Compounds specific to adenosine A.sub.3 receptor and uses thereof January 9, 2007
This invention pertains to compounds which specifically inhibit the adenosine A.sub.3 receptor and the use of these compounds to treat a disease associated with A.sub.3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the
7144711 AGS proteins and nucleic acid molecules and uses therefor December 5, 2006
A screening assay in yeast is disclosed wherein G-protein coupled-receptor independent activators and inhibitors of the pheromone pathway can be identified using a mammalian cDNA library. Novel Activator of G protein Signaling ("AGS") proteins, which are Ras-related proteins that stimula
7115647 Method of inhibiting neoplastic cells with indole derivatives October 3, 2006
A method for inhibiting neoplastic cells and related conditions by exposing them to substituted indole derivatives.
7101893 (2-Carboxamido)(3-amino)thiophene compounds September 5, 2006
A method of treatment of hyperproliferative disorders comprises administering an effective amount of a compound represented by Formula II: ##STR00001## or a pharmaceutically acceptable salt thereof.
7087613 Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyet August 8, 2006
A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynyl
7064122 Pancreatic lipase inhibitor compounds, their synthesis and use June 20, 2006
The subject invention features compounds having the structure: ##STR00001## wherein X is O, S, CH.sub.2 or NR.sub.5; Y is O or S; R.sub.1 is H, substituted or unsubstituted C.sub.1-C.sub.15 alkyl, C.sub.1-C.sub.8 alkylaryl, --C(O)OR.sub.4, --C(O)NR.sub.4R.sub.5, --CR.sub.6R.sub.6'OR
6916804 Pyrimidine A2b selective antagonist compounds, their synthesis and use July 12, 2005
The subject invention provides compounds having the structure: ##STR1##wherein R.sub.1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R.sub.2 is hydrogen, or a substituted or unsubstituted alkyl, --C(O)
6900221 Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochlorid May 31, 2005
The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions c
6878716 Compounds specific to adenosine A1 receptor and uses thereof April 12, 2005
This invention pertains to compounds which specifically inhibit the adenosine A.sub.1 receptor and the use of these compounds to treat a disease associated with A.sub.1 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the
6875575 Diagnostic methods for neoplasia April 5, 2005
This invention provides a method for diagnosing a patient with neoplasia.
1 2

 
 
  Recently Added Patents
Electronic currency, electronic wallet therefor and electronic payment systems employing them
Cleaning device, and image forming apparatus, process cartridge, and intermediate transfer unit each including the cleaning device
Systems and methods for dissipating an electric charge while insulating a structure
Spectrometer
Device and method including a soldering process
Method for driving electrophoretic display device, electrophoretic display device, and electronic device
Method for fabricating a nitrided silicon-oxide gate dielectric
  Randomly Featured Patents
Abrasive wipe
PBGA stiffener package
Multi-walled tubular baseball bats with barrel inserts of variable geometry
Defect review using image segmentation
In-line depth measurement for thru silicon via
Reception station on a shaping press and a set of tools for a said station
Fabrication of vascularized tissue using microfabricated two-dimensional molds
Vehicle frame with stress relief feature
Film sheet registration mechanism
Froth flotation using lanolin modifier